Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2007

01.12.2007 | Clinical Trials

Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities

verfasst von: John H. Stewart, IV, MD, Alain G. Bertoni, MD, MPH, Jennifer L. Staten, BS, Edward A. Levine, MD, Cary P. Gross, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI).

Methods

The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000–2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis.

Results

Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio[OR] vs whites 0.67, P<0.001), Hispanic (0.54%, OR 0.76, P<0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P<0.001). Patients 65–74 years of age (EF 0.45%) were less likely to be enrolled than those 20–44 years of age (EF=2.28%, OR 0.20, P=0.001).

Conclusions

The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed.
Literatur
1.
Zurück zum Zitat Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–2067PubMedCrossRef Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–2067PubMedCrossRef
2.
Zurück zum Zitat Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996; 88:812–816PubMedCrossRef Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996; 88:812–816PubMedCrossRef
3.
Zurück zum Zitat Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720–2726PubMedCrossRef Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720–2726PubMedCrossRef
4.
Zurück zum Zitat Tournoux C, Katsahian S, Chevret S, et al. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 2006; 106:258–270PubMedCrossRef Tournoux C, Katsahian S, Chevret S, et al. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 2006; 106:258–270PubMedCrossRef
5.
Zurück zum Zitat Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg 2004; 199:644–651PubMedCrossRef Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg 2004; 199:644–651PubMedCrossRef
6.
Zurück zum Zitat Gross CP, Murthy V, Li Y, et al. Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 2004; 96:1063–1069PubMedCrossRef Gross CP, Murthy V, Li Y, et al. Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 2004; 96:1063–1069PubMedCrossRef
7.
Zurück zum Zitat Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995; 87:1747–1759PubMedCrossRef Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995; 87:1747–1759PubMedCrossRef
8.
Zurück zum Zitat Gbadegesin S, Wendler D. Protecting communities in health research from exploitation. Bioethics 2006; 20:248–253PubMedCrossRef Gbadegesin S, Wendler D. Protecting communities in health research from exploitation. Bioethics 2006; 20:248–253PubMedCrossRef
9.
Zurück zum Zitat Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004; 22:730–734PubMedCrossRef Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004; 22:730–734PubMedCrossRef
11.
Zurück zum Zitat Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans’ willingness to participate in medical research studies. Cancer 2001; 91:233–236PubMedCrossRef Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans’ willingness to participate in medical research studies. Cancer 2001; 91:233–236PubMedCrossRef
12.
Zurück zum Zitat Mouton CP, Harris S, Rovi S, et al. Barriers to black women’s participation in cancer clinical trials. J Natl Med Assoc 1997; 89:721–727PubMed Mouton CP, Harris S, Rovi S, et al. Barriers to black women’s participation in cancer clinical trials. J Natl Med Assoc 1997; 89:721–727PubMed
13.
Zurück zum Zitat Shavers-Hornaday VL, Lynch CF, Burmeister LF, et al. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997; 2:31–45PubMedCrossRef Shavers-Hornaday VL, Lynch CF, Burmeister LF, et al. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997; 2:31–45PubMedCrossRef
14.
Zurück zum Zitat Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 2006; 24:413–418PubMedCrossRef Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 2006; 24:413–418PubMedCrossRef
15.
Zurück zum Zitat Lara PN Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19:1728–1733PubMed Lara PN Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19:1728–1733PubMed
16.
Zurück zum Zitat Gross CP, Herrin J, Wong N, et al. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol 2005; 23:4755–4763PubMedCrossRef Gross CP, Herrin J, Wong N, et al. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol 2005; 23:4755–4763PubMedCrossRef
17.
Zurück zum Zitat Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23:3802–3810PubMedCrossRef Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23:3802–3810PubMedCrossRef
18.
Zurück zum Zitat Cohen JJ, Gabriel BA, Terrell C. The case for diversity in the health care workforce. Health Aff (Millwood) 2002; 21:90–102CrossRef Cohen JJ, Gabriel BA, Terrell C. The case for diversity in the health care workforce. Health Aff (Millwood) 2002; 21:90–102CrossRef
Metadaten
Titel
Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities
verfasst von
John H. Stewart, IV, MD
Alain G. Bertoni, MD, MPH
Jennifer L. Staten, BS
Edward A. Levine, MD
Cary P. Gross, MD
Publikationsdatum
01.12.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9500-y

Weitere Artikel der Ausgabe 12/2007

Annals of Surgical Oncology 12/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.